Aurinia Pharmaceuticals (AUPH) Interest Expenses (2018 - 2026)

Aurinia Pharmaceuticals' Interest Expenses history runs 9 years deep, the most recent figure standing at $1.0 million for Q1 2026.

• Quarterly Interest Expenses fell 98.77% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.5 million (down 104.21% YoY) and the FY2025 annual result came in at $54.1 million, down 64.99% from the prior year.
• Interest Expenses was $1.0 million for Q1 2026 at Aurinia Pharmaceuticals, up from -$2.2 million in the prior quarter.
• Across five years, Interest Expenses topped out at $92.9 million in Q2 2024 and bottomed at -$2.6 million in Q4 2024.
• A 5-year average of $18.4 million and a median of $1.4 million in 2024 frame the typical range for Interest Expenses.
• Peak annual rise in Interest Expenses reached 142880.0% in 2024, while the deepest fall reached 977.63% in 2024.
• Aurinia Pharmaceuticals' Interest Expenses stood at -$897000.0 in 2022, then surged by 132.89% to $295000.0 in 2023, then tumbled by 977.63% to -$2.6 million in 2024, then gained by 15.68% to -$2.2 million in 2025, then surged by 146.36% to $1.0 million in 2026.
• Business Quant data shows AUPH's Interest Expenses at $1.0 million in Q1 2026, -$2.2 million in Q4 2025, and $7.2 million in Q3 2025.